How Kimchi Pharma Probiotics Can Help Your Gut Health Kumar Jeetendra | July 4, 2025 The intersection where ancient techniques of fermentation meet modern pharmaceutical technology. That is the goal of kimchi Pharma Probiotics, which aims to strengthen dietary supplements for gut health with rigorous scientific refinement inspired by Korea’s representative fermented dish. The increased consumption of processed foods, coupled with the stressed lifestyles of people, has emerged as a …
Alembic Gets USFDA Nod for Doxorubicin Liposome Injection Kumar Jeetendra | June 30, 2025 30th June, 2025 Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent …
What is Validation in Pharma and Why Does It Matter? Kumar Jeetendra | June 8, 2025 The world of pharmaceuticals encompasses a broad scope on law and ethics. The need for safety, effectiveness, and quality is not only vital, but a legal and ethical prerequisite. This is where ‘validation’ comes into play. But what validation means in the pharma world and why it’s important? What Validation Means Validation refers to having …
Cipla Achieves Water Positivity Milestone in India Operations Kumar Jeetendra | June 5, 2025 Mumbai, June 05, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has been certified as a water positive organisation by Bureau Veritas (BVQi) for its India operations in line with its sustainability targets. This milestone reinforces Cipla’s focused efforts to be a responsible corporate citizen and limit …
Alembic Pharma Gets USFDA Nod for Amlodipine-Atorvastatin Tablets Kumar Jeetendra | May 23, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Amlodipine and Atorvastatin Tablets USP, 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 …
Alembic Pharma Gets USFDA Nod for Rivaroxaban Tablets Kumar Jeetendra | May 15, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Xarelto Tablets, 2.5 …
Alembic Pharma Gets USFDA Approval for Divalproex Sodium Capsules, 125 mg Kumar Jeetendra | December 20, 2024 Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Divalproex Sodium Delayed-Release Capsules USP, 125 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Depakote Sprinkle Capsules, 125 mg, of AbbVie Inc. Alembic …
Cipla launches CipAir®: AI-Powered App Revolutionizing Asthma Screening in India Kumar Jeetendra | December 18, 2024 Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced the launch of CipAir®️, a mobile application designed to enable timely and convenient first line of screening for asthma in India. This first-of-its-kind technology is clinically validated through a multi-centric pan-India study. It aims to empower people by helping them understand their …
Pharma’s Green Revolution: Sustainable Practices in Drug Manufacturing Kumar Jeetendra | December 6, 2024 Amidst the number of industries showing interest in practicing sustainability, the pharmaceutical sector is also not lagging behind. The industry is in the process of change as a result of environmental concerns, regulatory needs, and increasing consumer knowledge. This transformation in drug manufacturing has been labeled as the Green Revolution—where new emerging practices mean that …
Alembic Pharmaceuticals announces USFDA Final Approval for Nelarabine Injection Kumar Jeetendra | August 13, 2024 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nelarabine Injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial). The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Arranon Injection, 250 mg/50 mL …
Dr. Reddy’s Duvvada Formulations Manufacturing Facility Receives USFDA EIR Kumar Jeetendra | August 13, 2024 Microbioz India, August 13th, 2024– Dr. Reddy’s Laboratories has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations manufacturing facility in Duvvada, Visakhapatnam, a remarkable regulatory achievement. The issuance of the EIR indicates that an earlier inspection has been completed and the factory is meeting strict regulatory …
Cipla announces additional investment in Achira Kumar Jeetendra | May 16, 2024 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for further investment of up to INR 26 crore (approx.) in Optionally Convertible Preference Shares of Achira Labs Private Limited, associate company (hereafter referred to as “Achira”) in four tranches, subject to completion of …
